Sinclair Pharma PLC (LON:SPH)‘s stock had its “buy” rating reaffirmed by stock analysts at N+1 Singer in a research report issued on Wednesday.

SPH has been the topic of several other research reports. Peel Hunt reiterated a “buy” rating and issued a GBX 68 ($0.89) price target on shares of Sinclair Pharma PLC in a report on Wednesday. Royal Bank Of Canada restated an “outperform” rating on shares of Sinclair Pharma PLC in a report on Thursday, September 15th. Stifel Nicolaus boosted their target price on shares of Sinclair Pharma PLC from GBX 49 ($0.64) to GBX 63 ($0.82) and gave the company a “buy” rating in a report on Wednesday, September 14th. Finally, Jefferies Group dropped their target price on shares of Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a “buy” rating on the stock in a report on Wednesday, June 15th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of GBX 57 ($0.74).

Sinclair Pharma PLC (LON:SPH) opened at 27.5749 on Wednesday. Sinclair Pharma PLC has a 52-week low of GBX 26.25 and a 52-week high of GBX 61.33. The company’s market cap is GBX 137.04 million. The company’s 50-day moving average is GBX 29.67 and its 200 day moving average is GBX 32.57.

Sinclair Pharma PLC Company Profile

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.